Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that the National Medical Products Administration (NMPA) has accepted for review its market filing for SHR-1701 in combination with fluorouracil and platinum for the first-line treatment of locally advanced unresectable, recurrent, or metastatic adenocarcinoma of the stomach and gastroesophageal junction.
SHR-1701 is a novel fusion protein that targets both programmed-death ligand (PD-L1) and TGF-βRII, designed to enhance the activation of effector T cells, improve immune regulation within the tumor microenvironment, and boost the immune system’s ability to eliminate tumor cells. This innovative therapy is unique, with no similar product currently available on the global market. Phase III clinical study results have demonstrated that SHR-1701 in combination with chemotherapy significantly extended overall survival in patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma, while also exhibiting a favorable safety profile.- Flcube.com
